 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...1011121314151617181920...170171» |
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal, Adherence: Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding. (Pubmed Central) - Oct 31, 2023
Dr DeRemer is a stockholder of Portola Pharmaceuticals and reported receiving personal fees for advisory board meeting from BMS. No other disclosures were reported.
- | rivaroxaban / Generic mfg.
Journal: Late Onset of Rivaroxaban-Associated Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. (Pubmed Central) - Oct 30, 2023
Given the broad and rapidly increasing use of novel anticoagulants, it is important to raise awareness of this potential complication. Prompt discontinuation of the drug and initiation of immunosuppressant treatment in severe cases may be lifesaving.
- | rivaroxaban / Generic mfg.
Journal: Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation. (Pubmed Central) - Oct 28, 2023
Reduced-dose rivaroxaban was associated with lower risks of all-cause mortality and hospitalization for heart failure in older patients with nonvalvular atrial fibrillation. Future studies can investigate the effect of reduced-dose rivaroxaban on prognoses in elderly individuals ?85 years in the west.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Safety and Efficacy of Uninterrupted Oral Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation with Different Techniques. (Pubmed Central) - Oct 28, 2023
Future studies can investigate the effect of reduced-dose rivaroxaban on prognoses in elderly individuals ?85 years in the west. Our results corroborate the safety and the efficacy of uninterrupted DOAC strategy in patients undergoing CA for AF, regardless of the ablation technique.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding. (Pubmed Central) - Oct 26, 2023
Our results corroborate the safety and the efficacy of uninterrupted DOAC strategy in patients undergoing CA for AF, regardless of the ablation technique. The use of aPCC for the management of apixaban- or rivaroxaban-related major bleeding is effective in most cases and is associated with a low risk of thromboembolism.
- ||| Trial completion, Enrollment change, HEOR, Real-world evidence, Real-world: REATTAIN: Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (clinicaltrials.gov) - Oct 26, 2023
P=N/A, N=134897, Completed, Sponsor: Bayer
The use of aPCC for the management of apixaban- or rivaroxaban-related major bleeding is effective in most cases and is associated with a low risk of thromboembolism. Active, not recruiting --> Completed | N=70000 --> 134897
- ||| rivaroxaban / Generic mfg., aspirin / Generic mfg.
Trial completion: XATOC: A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs (clinicaltrials.gov) - Oct 25, 2023
P=N/A, N=3189, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | N=70000 --> 134897 Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg.
Journal: Development of a validated RP-HPLC method for rivaroxaban quantification in pharmaceutical formulation and human blood plasma. (Pubmed Central) - Oct 24, 2023
Active, not recruiting --> Completed The method was also precise, accurate, robust and rugged and showed specificity in all applied stress conditions i.e. photolytic (200-800nm, 3h) thermal (70
- | rivaroxaban / Generic mfg.
Journal: Sucrose Acetate Isobutyrate (SAIB) and Glyceryl Monooleate (GMO) Hybrid Nanoparticles for Bioavailability Enhancement of Rivaroxaban: An Optimization Study. (Pubmed Central) - Oct 24, 2023
In conclusion, the study found that using GMO-SAIB as co-formers effectively enhanced the bioavailability of RXB. The authors recommend using the hybrid nanoparticles technique and suggest further research to enhance its effectiveness for drug delivery.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial completion, Enrollment change, Surgery: Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation (clinicaltrials.gov) - Oct 24, 2023
P3, N=100, Completed, Sponsor: Massachusetts General Hospital
The authors recommend using the hybrid nanoparticles technique and suggest further research to enhance its effectiveness for drug delivery. Recruiting --> Completed | N=300 --> 100
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Trends in drug spending of oral anticoagulants for atrial fibrillation, 2014-2021. (Pubmed Central) - Oct 23, 2023
Recruiting --> Completed | N=300 --> 100 There was a substantial increase in the overall cost burden of OACs and OAC initiation rates in patients with newly diagnosed AF in 2014-2021; these findings provide insights into the current and anticipated impact of rising drug prices on patients' and payers' financial burden.
- || warfarin / Generic mfg.
Observational data, Review: Risk of osteoporosis in patients treated with direct oral anticoagulants vs. warfarin: an analysis of observational studies. (Pubmed Central) - Oct 22, 2023
This study may give us insight into safe anticoagulation strategies for patients who are at high risk of developing osteoporosis. https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023401199.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Retrospective data, Journal, Adherence: Adherence and persistence to direct factor Xa inhibitors in the community following newly diagnosed venous thromboembolism: a retrospective pharmacy-linkage study. (Pubmed Central) - Oct 22, 2023
In patients with newly diagnosed VTE treated with a factor Xa inhibitor, adherence rates are high at >80%, with females and those prescribed apixaban exhibiting higher adherence. These findings may assist clinicians in identifying those patients with VTE at risk of poor adherence.
- || Review, Journal: Warfarin faring better: Vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. (Pubmed Central) - Oct 22, 2023
The results of the INVICTUS trial (Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies), which compared rivaroxaban with a VKA in patients with rheumatic heart disease associated AF, and the PROACT Xa trial (A Trial to Determine if Participants with an On-X Aortic Valve Can be Maintained Safely on Apixaban), which compared apixaban with warfarin in patients with an On-X valve in the aortic position, support the use of VKAs for these indications. In this paper, we review the results of these trials, provide perspective on why VKAs were superior to DOACs, and discuss future directions for anticoagulation in these disorders.
- | rivaroxaban / Generic mfg., heparin sodium injection / Generic mfg.
Journal: Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial. (Pubmed Central) - Oct 22, 2023
Therapeutic anticoagulation with rivaroxaban compared to prophylactic anticoagulation with a heparin did not improve surrogates of clinical outcome in patients with moderate to severe COVID-19. Whether initial rivaroxaban at therapeutic doses might be superior to thromboprophylaxis in patients with COVID-19 and a high risk as defined by D-dimer ?>?2 ULN needs confirmation in further studies.
- | rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Preclinical, Journal: In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients. (Pubmed Central) - Oct 22, 2023
P
Twelve hours after taking rivaroxaban, administering 0.5 mg/kg of enoxaparin may provide adequate and safe anticoagulant activity for immediate PCI. This experimental study result should confirm with clinical trials (NCT05541757).
- | rivaroxaban / Generic mfg.
Journal: Left atrial appendage closure device thrombosis despite therapeutic anticoagulation with rivaroxaban. (Pubmed Central) - Oct 22, 2023
This experimental study result should confirm with clinical trials (NCT05541757). No abstract available
- || Ameile (aumolertinib) / Jiangsu Hansoh Pharma, EQRx
PK/PD data, Preclinical, Journal: In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban. (Pubmed Central) - Oct 20, 2023
The results of qRT-PCR showed that almonertinib reduced the expression of Cyp3a1 in liver and intestine, and Abcb1a, Abcg2 in intestine and kidney. The pharmacokinetic results suggest that it is important to take special care of the interactions of these drugs in clinical applications.
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) (clinicaltrials.gov) - Oct 19, 2023
P2/3, N=42, Completed, Sponsor: Mazandaran University of Medical Sciences
The pharmacokinetic results suggest that it is important to take special care of the interactions of these drugs in clinical applications. Recruiting --> Completed | Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Oct 2022 --> Apr 2023
- || Savaysa (edoxaban) / Daiichi Sankyo
Review, Journal: Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review. (Pubmed Central) - Oct 16, 2023
Further research is needed to fully understand the pleiotropic effects of DOACs on ECs, their underlying mechanisms, as well as the heterogeneity between various DOACs. Such studies can pave the way for identifying biomarkers that can help personalize pharmacotherapy with this valuable class of drugs.
- | rivaroxaban / Generic mfg.
Journal: Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients. (Pubmed Central) - Oct 14, 2023
Low-dose rivaroxaban is potentially effective and safe in cancer patients that require prevention of recurrent VTE. Large-scale studies are needed to confirm these findings.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Retrospective data, Journal: Comparison of medical documentation between pharmacist-led anticoagulation clinics and physician-led anticoagulation clinics: A retrospective study. (Pubmed Central) - Oct 12, 2023
Pharmacists were more comprehensive in their documentation than physicians in anticoagulation clinics. Unified clinic documentation can ensure consistent documentation within EHRs across all disciplines.
- rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
SAFETY OF DOACS IN PATIENTS WITH CHILD-PUGH CLASS C CIRRHOSIS AND ATRIAL FIBRILLATION (Room 312) - Oct 11, 2023 - Abstract #AASLD2023AASLD_1006;
DOACs are a safer alternative to warfarin with a lower risk of intracranial hemorrhage and GI bleed. The higher rates of embolic stroke in patients on AC is likely a selection bias as patients with stroke are more likely to be placed on AC.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
REDUCE DOSE SAFETY OF DIRECT ORAL ANTICOAGULANTS IN CIRRHOTIC PATIENTS AND PORTAL VEIN THROMBOSIS WITH COEXISTENT SIGNIFICANT THROMBOCYTOPENIA: A MULTI-COUNTRY STUDY (Room 312) - Oct 11, 2023 - Abstract #AASLD2023AASLD_1003;
Patients with cirrhosis with significant thrombocytopenia were divided into two cohorts; the first cohort comprised patient receiving 50% reduced-dose DOAC (Apixaban or Rivaroxaban), and a second cohort did not receive any anticoagulation therapy. In a large multi-country study, the use of reduced dosed DOAC in patient with cirrhosis and significant thrombocytopenia was not significantly associated with major bleedings such as intracranial hemorrhage or gastrointestinal bleeding up to 12-months when compared with patient not on anticoagulation.
- Savaysa (edoxaban) / Daiichi Sankyo
A COMPARATIVE ANALYSIS OF OUTCOMES BETWEEN DIRECT ORAL ANTICOAGULANTS AND LOW-MOLECULAR-WEIGHT HEPARIN OR VITAMIN K ANTAGONISTS IN BUDD-CHIARI SYNDROME: A GLOBAL MULTICENTER PROPENSITY-MATCHED STUDY (Room 312) - Oct 11, 2023 - Abstract #AASLD2023AASLD_273;
LMWH or VKA treatment requires continuous monitoring, which may affect patient compliance. Our study suggests that DOACs could serve as an effective and safe long-term anticoagulation alternative for these patients.
- | rivaroxaban / Generic mfg.
Journal: Effect of hydrophilic polymers on the solubility and dissolution enhancement of rivaroxaban/beta-cyclodextrin inclusion complexes. (Pubmed Central) - Oct 9, 2023
Results of solubility enhancement and improvement in dissolution profile of model drug by ternary inclusion complexation were also supported by FTIR, DSC, XRD, and SEM analysis. So, it can be concluded that the ternary inclusion systems were more effective compared to the binary combinations in improving solubility as well as dissolution of hydrophobic model drug rivaroxaban.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial. (Pubmed Central) - Oct 9, 2023
So, it can be concluded that the ternary inclusion systems were more effective compared to the binary combinations in improving solubility as well as dissolution of hydrophobic model drug rivaroxaban. Bleeding occured in 25.9% in the warfarin group versus 11.5% in the rivaroxaban group (P
- | rivaroxaban / Generic mfg.
Preclinical, Journal: Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-?1 signaling pathways. (Pubmed Central) - Oct 7, 2023
Consistent with the findings of the animal experiments, RIV and FSLLRY inhibited the expression of fibrosis markers and suppressed the intracellular upregulation of transforming growth factor ?1 (TGF?1), as well as its downstream Smad2/3 phosphorylation effectors in Ang II-induced fibrosis, and PAR-2 agonist peptide (PAR-2 AP) reversed the inhibition effect of RIV. Our findings demonstrate that RIV attenuates MI-induced cardiac remodeling and improves heart function, partly by inhibiting the activation of the PAR-2 and TGF-?1 signaling pathways.
- | Journal: Characteristics of patients with Atrial Fibrillation treated with direct oral anticoagulants and New Insights into inappropriate dosing: Results from the French National PAF Registry. (Pubmed Central) - Oct 6, 2023
Independent predictors of inappropriate dosing were high CHA2DS2VASc scores and older age. Moreover, 46% of patients treated with low dose DOACs were inappropriately underdosed and more frequently occurred with apixaban.
- | rivaroxaban / Generic mfg.
Journal: Combination of Minimally Invasive Methods for the Treatment of Varicose Veins. (Pubmed Central) - Oct 6, 2023
The combination of minimally invasive methods is a safe and effective method for the treatment of lower extremity varicose veins. Further large-scale, prospective, multi-center studies are needed to further verify the findings of this study.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal, Real-world evidence, Real-world: Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism. (Pubmed Central) - Oct 5, 2023
This study revealed the feasibility of complementing RCTs with RWE studies by using claims data in patients with VTE. Future studies to consider the different demographic characteristics between RCT and RWE populations are needed.
- | rivaroxaban / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (clinicaltrials.gov) - Oct 3, 2023
P3, N=50, Recruiting, Sponsor: Kevin H.M. Kuo, MD, MSc, FRCPC
Future studies to consider the different demographic characteristics between RCT and RWE populations are needed. Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Jun 2024
- | rivaroxaban / Generic mfg.
Trial completion date, Trial primary completion date: Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=178, Recruiting, Sponsor: Chiayi Christian Hospital
Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Jun 2024 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- | rivaroxaban / Generic mfg.
Journal: Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J'xactly Study. (Pubmed Central) - Oct 2, 2023
Patients with PE with and without residual DVT did not have a different incidence of symptomatic PE recurrence. These results require additional study to be confirmed.
- Q-Force (quercetin) / Quercis Pharma, Temple University
Thiol isomerase inhibition with bacitracin or rutin increases tissue factor production in myelomonocytic HL-60 cells and isolated AML blasts (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1297;
The effect of thiol isomerase inhibition critically depends on the specific inhibitor and cell type. In some scenarios, antineoplastic therapy with PDI inhibitors might be accompanied by increased myeloid TF production and, thus, a potentially increased thrombotic risk.
- BMS-262084 / BMS, Innohep (tinzaparin) / LEO Pharma
Paraneoplastic factor XI (FXI) production contributes to a hypercoagulable state in hepatic cancer and is a potential resistance mechanism against FXI/FXIa-directed anticoagulation (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_904;
Conclusions : We suggest that FXI production is a common finding only in hepatic cancers. In this entity, however, dysregulated FXI synthesis can contribute to a hypercoagulable state and may critically affect the efficacy of FXI/FXIa-directed anticoagulation.
- BMS-262084 / BMS, Innohep (tinzaparin) / LEO Pharma
Effect of factor XI/XIa inhibition in an in-vitro model of tumor cell-induced coagulation activation (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_903;
In this entity, however, dysregulated FXI synthesis can contribute to a hypercoagulable state and may critically affect the efficacy of FXI/FXIa-directed anticoagulation. Taken together, our study indicates that FXI/FXIa inhibition might be a promising approach in CAT prophylaxis and treatment, especially in tumors with weak TF PCA expression.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Journal, Adherence: Prevalence and Predictors of Nonadherence to Direct Oral Anticoagulant Treatment in Patients with Atrial Fibrillation. (Pubmed Central) - Sep 29, 2023
Conclusion ?One-year nonadherence to DOACs was low yet relevant in patients with AF newly prescribed a DOAC. Understanding the predictors for nonadherence may help identify patients at risk.
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk (clinicaltrials.gov) - Sep 28, 2023
P=N/A, N=645, Completed, Sponsor: Maatschap Cardiologie Zwolle
Understanding the predictors for nonadherence may help identify patients at risk. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023
- || rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
Biomarker, PK/PD data, Journal: Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy. (Pubmed Central) - Sep 28, 2023
of rivaroxaban of >137 pg/mL (5.94 OR, (95% CI, 3.13-12.99; p < 0.004)) and carriage of the T allelic variant polymorphism ABCB1 rs4148738 (8.97 OR (95% CI, 1.48-14.49; p < 0.017)), as well as for the BARC scale (5.76 OR (95% CI, 2.36-9.87; p < 0.018)). Measuring residual steady-state rivaroxaban concentrations and determining the carriage of the T allelic variant polymorphism ABCB1 rs4148738 may be applicable to high-risk patients for subsequent antithrombotic therapy modification.
- | Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
Trial completion date, Trial initiation date: THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) (clinicaltrials.gov) - Sep 28, 2023
P4, N=6660, Not yet recruiting, Sponsor: Imperial College London
Measuring residual steady-state rivaroxaban concentrations and determining the carriage of the T allelic variant polymorphism ABCB1 rs4148738 may be applicable to high-risk patients for subsequent antithrombotic therapy modification. Trial completion date: Aug 2026 --> Dec 2026 | Initiation date: Jun 2023 --> Oct 2023
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China. (Pubmed Central) - Sep 27, 2023
The ranking of DOACs could help to support the decision-making in clinical practice. The framework could provide a reference for comprehensive evaluation of other drugs.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Observational data, Journal: Lower mortality with andexanet (Pubmed Central) - Sep 27, 2023
P=N/A
The framework could provide a reference for comprehensive evaluation of other drugs. In this large observational study, treatment with andexanet
- || rivaroxaban / Generic mfg.
PK/PD data, Journal: Effect of a High-Fat Diet on the Pharmacokinetics and Safety of Rivaroxaban in Healthy Chinese Subjects. (Pubmed Central) - Sep 23, 2023
The incidence of adverse events (AEs) was similar between the fasted and fed states, and no serious AEs were observed. Food significantly increased the exposure to rivaroxaban 10
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal: Adrenal hemorrhage and non-ST elevation myocardial infarction: an antiphospholipid syndrome dilemma. (Pubmed Central) - Sep 22, 2023
Non-ST elevation myocardial infarction, as well as new-onset left-sided adrenal hemorrhage, were diagnosed. The patient developed adrenal insufficiency; therefore, corticosteroids were administered, and warfarin was resumed to prevent further thrombotic episodes.
- || rivaroxaban / Generic mfg.
Observational data, Retrospective data, Review, Journal: Comparisons of Effectiveness and Safety between On-label Dosing, Off-label Underdosing and Off-label Overdosing in Asian and Non-Asian Atrial Fibrillation Patients Treated with Rivaroxaban: A Systematic Review and Meta-analysis of Observational Studies. (Pubmed Central) - Sep 22, 2023
Rivaroxaban dosing regimen following J-ROCKET criteria may serve as an alternative to ROCKET-AF criteria for the Asian population with NVAF, whereas the dosing regimen following ROCKET AF criteria was more favorable for the non-Asian population. Use of rivaroxaban 10mg despite of CrCl>50ml/min was associated with a higher risk of thromboembolism but a lower risk of major bleeding, while use of rivaroxaban 20mg despite of CrCl<50ml/min was associated with worse outcome in most clinical events.
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Journal: Who may benefit from low-dose Rivaroxaban plus Aspirin? Practical implications for outpatients with cardiovascular disease. (Pubmed Central) - Sep 22, 2023
Therefore, DPI is recommended in patients with CAD (+/- PAD) or symptomatic PAD at high ischaemic risk. The purpose of this review is to examine the clinical benefits and practical implications of DPI in CAD and PAD patients.
- | Bevyxxa (betrixaban) / AstraZeneca
Journal: An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis. (Pubmed Central) - Sep 20, 2023
Therefore, this article aims to explore the challenges faced during the approval process of betrixaban and provide a comprehensive review of the literature on its advantages and disadvantages as a long-term prophylaxis approach for VTE. Furthermore, we aim to identify the ambiguous points that require further investigation in future studies.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. (Pubmed Central) - Sep 20, 2023
Furthermore, we aim to identify the ambiguous points that require further investigation in future studies. In individuals with atrial fibrillation potentially eligible for DOAC therapy, the DOAC Score can help stratify patients on the basis of expected bleeding risk.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: A medication reconciliation failure: A case report and incident analysis. (Pubmed Central) - Sep 18, 2023
Anticoagulants are ranked first for the highest priority to receive a medication reconciliation. To achieve an optimal level of medication reconciliation, we ought to recognise and correct latent failures.